Yichang Humanwell Partners with DP Technology to Leverage Hermite Platform for Drug Discovery
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced a strategic partnership with DP...
Wusheng Erlunbao: Sinopharm’s First‑of‑Its‑Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval
The Wuhan Institute of Biological Products Co., Ltd., a subsidiary of Sinopharm Group Co., Ltd....
Lepu Medical Secures NMPA Approval for Innovative Sodium Hyaluronate Dermal Filler
China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) announced today that its self‑developed Class III...
InxMed Secures HK$100 M Private Placement from TruMed Health
On August 26, 2025, Hong Kong‑listed China-based InxMed (Nanjing) Co., Ltd (HKG: 2509) announced that it has...
Chengdu Ucello’s UC101 CAR‑T Gains NMPA Approval
China‑based Chengdu Ucello Biotechnology Co., Ltd. announced that its Investigational New Drug (IND) application for...
Henlius, Serplulimab and Abbott Drive Robust 2025 Financials
Shanghai Henlius Biotech, Inc. (HKG: 2696) released its 2025 first‑half financials, reporting a 2.7 % year‑on‑year...
BeOne Secures $950 M Deal with Royalty Pharma for Tarlatamab Rights
On August 26, 2025, BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that it had...
RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin
RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, reported its 2025 semi-annual...
Xuanzhu Biopharma’s XZP-3621 Approved for ALK-Positive NSCLC in China
Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460),...
Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs
Vibrant Therapeutics, an innovative biotech company specializing in next-generation intelligent macromolecule drugs, announced on August...
Dizal Pharma Reports 74.4% Revenue Growth in 2025 Semi-Annual Results
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192), a China-based company, reported its 2025 semi-annual results,...
Daiichi Sankyo’s Enhertu Submitted for Priority Review in China for HER2-Positive Breast Cancer
On August 22, 2025, Daiichi Sankyo (TYO: 4568) submitted a marketing authorization application for Enhertu...
DATROWAY Approved in China for HR-Positive, HER2-Negative Breast Cancer
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) announced that DATROWAY has been approved...
Yantai Dongcheng’s 225Ac-LNC1011 Injection Gains FDA Approval for Prostate Cancer Trial
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675), a China-based company, announced that its 225Ac-LNC1011...
Ocumension’s OT-301 Meets Primary Endpoint in Denali Phase III Trial
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) , a China-based pharmaceutical company, announced on August 21,...
Zhejiang Medicine Receives NMPA Approval for Phase 1 Trial of XC2309 Injection
Zhejiang Medicine Co., Ltd. (SHA: 600216), a China-based pharmaceutical company, announced that it has received...
Shanghai Bao Pharma Files for Hong Kong IPO, Aiming to Boost Biologics Development
Shanghai Bao Pharmaceuticals Co. Ltd., a company leveraging synthetic biology to develop recombinant biologics, submitted...
Zhongsheng Pharma’s Onradivir Granted Drug Registration in Macau
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that its onradivir tablets have received a...
Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners
Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), based in China, announced plans to co-establish the...
Hengrui Pharmaceuticals Reports 15.88% Revenue Growth in 2025 Semi-Annual Results
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) has released its 2025 semi-annual report, highlighting...